FOLH1 and triple-negative breast carcinoma: Regarding the clinical application of PSMA-RLT (Table 2), a 38-year-old female with an aggressive triple-negative breast carcinoma, previously unresponsive to chemotherapy and bevacizumab, received [177Lu]Lu-PSMA-RLT (2 cycles 7.5 GBq) based on intense tumor tracer uptake on PSMA imaging (SUV not reported).